Inclusion Criteria:

- Histological or cytological confirmation of an advanced solid malignant tumour or
lymphoma which is refactory to standard therapies or for which no standard therapy
exists, patients with measurable or non-measurable disease (according to RECIST
criteria)

- WHO performance status 0-2

- Evidence of post-menopausal status or negative urine/serum pregnancy test for
pre-menopausal female patients

Exclusion Criteria:

- Patients with severe laboratory abnormalities for haematology, liver or renal
function. Also treatment with any haemopoietic growth factors are not allowed within
two weeks from first dose of study drug.

- Any investigational agents or study drugs from a previous clinical study within 30
days, any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of
the first dose of study treatment

- Patients with severe cardiac condition of ischemia, impaired ventricular function and
arrhythmias, evidence of severe or uncontrolled systemic or current unstable or
uncompensated respiratory or cardiac conditions